imagabalin imagabalin imagabalin (inn, usan; pd-0332334) was an investigational drug that acted as a ligand for the α2δ subunit of the voltage-dependent calcium channel, with some selectivity for the α2δ1 subunit over α2δ2. it was under development by pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. it reached phase-iii clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer. the drug is no longer under development. imagabalinclinical dataother namespd-0332334; pd-332,334atc codenoneidentifiers iupac name (3s,5r)-3-amino-5-methyloctanoic acid cas number610300-07-7 610300-00-0 (hydrochloride)pubchem cid10236037chemspider8411525uniindg6931b7hkeggd09627comptox dashboard (epa)dtxsid00976534 chemical and physical dataformulac9h19no2molar mass173.256 g·mol−13d model (jsmol)interactive image smiles o=c(o)c(n)c(ccc)c inchi inchi=1s/c9h19no2/c1-3-4-7(2)5-8(10)6-9(11)12/h7-8h,3-6,10h2,1-2h3,(h,11,12)/t7-,8+/m1/s1key:jxehxyfsioytah-sfyzadrcsa-n